Browsing Cancer Therapeutics by author "Zvelebil, Marketa Juditha"
Now showing items 1-2 of 2
-
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi, A; Martin, L-A; Gao, Q; Pancholi, S; Mackay, A; et al. (AMER ASSOC CANCER RESEARCH, 2013-06-15)Most breast cancers at diagnosis are estrogen receptor-positive (ER(+)) and depend on estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors has therefore become a first-line endocrine ... -
MoKCa database--mutations of kinases in cancer.
Richardson, CJ; Gao, Q; Mitsopoulous, C; Zvelebil, M; Pearl, LH; et al. (OXFORD UNIV PRESS, 2009-01-01)Members of the protein kinase family are amongst the most commonly mutated genes in human cancer, and both mutated and activated protein kinases have proved to be tractable targets for the development of new anticancer ...